Sullivan John James received 1,774 derivative securities from MESA LABORATORIES INC /CO/ on 2026-09-09, leaving him with 1,774 derivative securities after the award. The transaction represented about 100.0% of his resulting derivative-securities holding, giving investors a precise view of the reported post-transaction position.
Key Highlights
- The filing records the transaction.
- Sullivan John James held 1,774 derivative securities after the transaction.
- Sullivan John James’s post-transaction holding was 1,774 derivative securities.
Sullivan John James was awarded 1,774 derivative securities of MESA LABORATORIES INC /CO/. Following the transaction, he owned 1,774 derivative securities in his resulting holding. The filing lists SEC transaction code A for the transaction.
1,774 Derivative Securities Awarded
The recorded quantity was 1,774 derivative securities, while the post-transaction holding also stood at 1,774 derivative securities. The reported transaction represented about 100.0% of Sullivan’s resulting derivative-securities holding. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: What did Sullivan John James receive from Mesa Laboratories?
A: Sullivan John James was awarded 1,774 derivative securities of MESA LABORATORIES INC /CO/. The filing lists SEC transaction code A for the transaction.
Q: What does the insider transaction mean for Mesa Laboratories investors?
A: Sullivan John James held 1,774 derivative securities after the transaction. The filing states that the transaction represented about 100.0% of that resulting derivative-securities holding.
Q: How many derivative securities did Sullivan John James own after the award?
A: Sullivan John James’s post-transaction holding was 1,774 derivative securities. The award represented about 100.0% of that resulting derivative-securities position. The filing reports this holding after the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.